• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by ClearPoint Neuro Inc.

    5/16/24 4:18:34 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care
    Get the next $CLPT alert in real time by email
    S-8 1 clpt-formsx82024x5thar2013.htm S-8 Document

    shar 
    As filed with the Securities and Exchange Commission on May 16, 2024
     
    Registration Statement No. 333-               
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM S-8
     
    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933
     
     
     
    CLEARPOINT NEURO, INC.
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware58-2394628
    (State or other jurisdiction
    of incorporation or organization)
     
    (I.R.S. Employer Identification No.)
    120 S. Sierra Ave., Suite 100
    Solana Beach, California
    92075
    (Address of principal executive offices)(Zip Code)
     
     
     
    FIFTH AMENDED AND RESTATED 2013 INCENTIVE COMPENSATION PLAN
     
    (Full title of the plans)
     
     
      
    Ellisa Cholapranee
    General Counsel and Secretary
    120 S. Sierra Ave., Suite 100
    Solana Beach, California 92075
    (Name and address of agent for service)
     
     
     

    (888) 287-9109
    (Telephone number, including area code, of agent for service) 
     
     
     
    With copies to:
    Richard F. Mattern, Esq.
    Bass, Berry & Sims PLC
    The Tower at Peabody Place – 100 Peabody Place, Suite 1300
    Memphis, TN 38103-3672
    (901) 543-5933
     
     
     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


    Large accelerated filer ☐
    Accelerated filer ☐
    Non-accelerated filer ☒
    Smaller reporting company ☒
    Emerging growth company ☐
        If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

      
     
     

     
    1



    REGISTRATION OF ADDITIONAL SECURITIES
    This Registration Statement relates solely to the registration of additional securities of the same class as other securities for which a registration statement on this form relating to an employee benefit plan is effective. Pursuant to General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of (i) the registration statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on October 25, 2013 (Registration No. 333-191908), (ii) the registration statement on Form S-8 filed by the Registrant with the Commission on August 17, 2015 (Registration No. 333-206432), (iii) the registration statement on Form S-8 filed by the Registrant with the Commission on October 3, 2017 (Registration No. 333-220783), (iv) the registration statement on Form S-8 filed by the Registrant with the Commission on June 3, 2020 (Registration No. 333-238907), and (v) the registration statement on Form S-8 filed by the Registrant with the Commission on June 1, 2022 (Registration No. 333-265349), with respect to the ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan, as amended and restated.



    2



    PART I
     
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
     
    Documents containing information required by Part I of this Registration Statement will be sent or given to employees, officers, directors or others as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the Note to Part I of Form S-8, such documents are not filed with the Commission either as a part of this Registration Statement or as prospectuses or prospectus supplements.
     



    PART II
     
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     
    Item 3. Incorporation of Documents by Reference.
     
    The following documents, which have been filed by the Registrant with the Commission, are incorporated by reference into this Registration Statement:
    •The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 12, 2024;
    •The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 filed on May 7, 2024;
    •The Registrant’s Current Reports on Form 8-K filed on March 1, 2024, and May 16, 2024 ; and
    •The description of the Registrant’s Common Stock set forth in the Registrant’s Registration Statement on Form 8A12B filed with the Commission on December 6, 2019 pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.
    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) subsequent to the filing of this Registration Statement (except for any portions of the Registrant’s current reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.


    3



    Item 8. Exhibits.
     
    The exhibits listed below are filed as part of or incorporated into this Registration Statement.
    Exhibit No. 
    Description
    4.1 
    Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2012).
    4.2
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 8, 2015).
    4.3
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 26, 2016).
    4.4
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2020).
    4.5
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 25, 2023).
    4.6
    Amended and Restated Bylaws of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 11, 2012).
     
    4.7 
    Second Amended and Restated Bylaws of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2020).
    4.8
    Third Amended and Restated Bylaws of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 17, 2021).
    4.9
    Fourth Amended and Restated Bylaws of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 14, 2022).
      
    4.10 
    Specimen of Common Stock Certificate of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2020).
       
    4.11 
    Fifth Amended and Restated 2013 Incentive Compensation Plan (incorporated by reference to Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 5, 2024).
       
    5.1* 
    Opinion of Bass, Berry & Sims PLC
       
    23.1* 
    Consent of Bass, Berry & Sims PLC (included in Exhibit 5.1)
       
    23.2* 
    Consent of Cherry Bekaert LLP
       
    24.1* 
    Power of attorney (included on signature page)
     
    107*
    Filing Fee Table
       
    4


    *Filed herewith.
    5


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Solana Beach, state of California, on May 16, 2024.
     
    CLEARPOINT NEURO, INC.

    By:
     /s/ Joseph M. Burnett
    Name: Joseph M. Burnett
    Title: Chief Executive Officer and President

     
    POWER OF ATTORNEY
     
    The undersigned directors and officers do hereby constitute and appoint Joseph M. Burnett and Danilo D’Alessandro and Ellisa Cholapranee and each of them, with full power of substitution, our true and lawful attorneys-in-fact and agents to do any and all acts and things in our name and behalf in our capacities as directors and officers, and to execute any and all instruments for us and in our names in the capacities indicated below, that such person may deem necessary or advisable to enable the registrant to comply with the Securities Act and any rules, regulations and requirements of the Securities and Exchange Commission in connection with this registration statement, including specifically, but not limited to, power and authority to sign for us, or any of us, in the capacities indicated below, any and all amendments hereto (including pre-effective and post-effective amendments or any other registration statement filed pursuant to the provisions of Rule 462(b) under the Securities Act); and we do hereby ratify and confirm all that such person or persons shall do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
     



    Signature Title Date
     
    /s/ Joseph M. Burnett
     Chief Executive Officer and Director May 16, 2024
    Joseph M. Burnett (Principal Executive Officer)  
     
    /s/ Danilo D’Alessandro
     Chief Financial Officer May 16, 2024
    Danilo D’Alessandro (Principal Financial and Accounting Officer)  
     
    /s/ R. John Fletcher
     Director May 16, 2024
    R. John Fletcher    
     
    /s/ Lynnette C. Fallon
     Director May 16, 2024
    Lynnette C. Fallon    
     
    /s/ Pascal E.R. Girin
     Director May 16, 2024
    Pascal E.R. Girin    
     /s/ B. Kristine Johnson Director May 16, 2024
    B. Kristine Johnson    
     /s/ Matthew B. Klein Director May 16, 2024
    Matthew B. Klein    
     
    /s/ Linda M. Liau
     Director May 16, 2024
    Linda M. Liau    
     
    /s/ Timothy T. Richards
     Director May 16, 2024
    Timothy T. Richards    

    Get the next $CLPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLPT

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    More analyst ratings

    $CLPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

    Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

    11/13/24 1:20:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro Reports Third Quarter 2024 Results

    Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

    11/7/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

    President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

    10/31/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    SEC Filings

    View All

    Amendment: ClearPoint Neuro Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - ClearPoint Neuro, Inc. (0001285550) (Filer)

    2/5/26 4:25:56 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    SEC Form D filed by ClearPoint Neuro Inc.

    D - ClearPoint Neuro, Inc. (0001285550) (Filer)

    2/5/26 8:07:29 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by ClearPoint Neuro Inc.

    EFFECT - ClearPoint Neuro, Inc. (0001285550) (Filer)

    1/23/26 12:15:30 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

    B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

    7/25/24 8:27:37 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on ClearPoint Neuro with a new price target

    Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

    10/24/23 6:18:03 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

    B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

    2/16/23 7:44:43 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Burnett Joseph sold $45,823 worth of shares (2,943 units at $15.57) (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/27/26 4:27:46 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    CEO and President Burnett Joseph sold $322,400 worth of shares (20,000 units at $16.12) and exercised 20,000 shares at a strike of $2.50 (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/13/26 5:00:03 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Chief Business Officer Stigall L. Jeremy was granted 1 shares, increasing direct ownership by 0.00% to 72,356 units (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    1/5/26 6:57:18 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLPT
    Financials

    Live finance-specific insights

    View All

    ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

    SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

    10/17/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

    SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

    7/17/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

    SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

    4/23/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Leadership Updates

    Live Leadership Updates

    View All

    ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

    SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

    9/20/22 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

    SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

    8/8/22 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

    SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

    7/15/21 4:30:00 PM ET
    $CLPT
    $ACLS
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Technology

    $CLPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/12/24 2:35:26 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/8/24 4:33:36 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/4/24 11:28:38 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care